NEW YORK, Nov. 22, 2024 /PRNewswire/ -- If You Paid for or Provided Reimbursement for Branded Tracleer or Bosentan, A Class Action Lawsuit May Affect Your Rights. A class action lawsuit is pending in the United States District Court for the District of Maryland (the "Court"). The Plaintiff in the lawsuit is asserting class action claims and alleges that Defendants Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US, Inc., and Janssen Research & Development, LLC (collectively "Defendants"

AstraZeneca's AZD1390 to Join GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma AZD1390 Arm Will Recruit Patients with Newly Diagnosed Glioblastoma LARKSPUR, Calif., Nov. 22, 2024 /PRNewswire/ -- The Global Coalition for Adaptive Research (GCAR) today announced that they have executed an agreement with AstraZeneca for the evaluation of AstraZeneca's compound, AZD1390, in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment - N

Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of popular weight loss and diabetes drugs. A new legal strategy could put Lilly one step ahead of compounders, if it’s successful. The case may come down to one amino acid. Lilly filed a lawsuit in September against the FDA and the Department of Health and Human Services, arguing that its next-generation “triple G” agonist retatrutide should be reclassified as a biologic, as oppos

NEW YORK--( BUSINESS WIRE )-- Particle Health , a Member of the CommonWell Health Alliance since 2019, will join the Alliances’s Qualified Health Information Network™ (QHIN™). This decision will allow Particle Health to deepen its partnership with CommonWell and work across the broader community to advance the goal of health interoperability under TEFCA. Particle Health and CommonWell have a long history of successful partnership having worked together since early 2019 in a national network. “ C

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s a

CHICAGO--( BUSINESS WIRE )--GE HealthCare (Nasdaq: GEHC) announces additional clinical applications now available as part of the OEC 3D mobile CBCT C-arm portfolio to help enable precise and efficient imaging during endoscopic bronchoscopy procedures in the practice of interventional pulmonology. Complex pulmonary and thoracic procedures require precise intraoperative imaging systems. To diagnose and biopsy a suspected lesion or region of interest in the lungs, physicians need to visualize and c

NEW YORK--( BUSINESS WIRE )-- OverT Bio , an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReady TM , in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH ), and CellReady TM . This grant will support OverT Bio’s ongoing development efforts that will lead to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverT arget TM and OverT CR TM . The G-Rex Gran

GAINESVILLE, Fla., Nov. 22, 2024 /PRNewswire/ -- Exactech, a global medical technology leader, announced the successful first surgical cases using the new Equinoxe® Central Screw (CS) Baseplate implant, marking a milestone in advancing shoulder care. Continue Reading Exactech's Equinoxe® Central Screw (CS) Baseplate implant leverages more than 20 years of clinical experience from Exactech's Equinoxe Shoulder System, rounding out the shoulder portfolio and enhancing glenoid options for surgeons,

CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. Th

FORT LAUDERDALE, Fla., Nov. 22, 2024 /PRNewswire/ -- The boards of the North Broward Hospital District, doing business as Broward Health, and Nicklaus Children's Health System, have officially approved an affiliation agreement to collaborate in delivering world-class pediatric care. Beginning in early 2025, the two organizations will work together to expand and enhance pediatric services across Broward County, with a goal of fully integrating and enriching the pediatric care offerings by latter